Your browser doesn't support javascript.
loading
A proteome-scale map of the SARS-CoV-2-human contactome.
Kim, Dae-Kyum; Weller, Benjamin; Lin, Chung-Wen; Sheykhkarimli, Dayag; Knapp, Jennifer J; Dugied, Guillaume; Zanzoni, Andreas; Pons, Carles; Tofaute, Marie J; Maseko, Sibusiso B; Spirohn, Kerstin; Laval, Florent; Lambourne, Luke; Kishore, Nishka; Rayhan, Ashyad; Sauer, Mayra; Young, Veronika; Halder, Hridi; la Rosa, Nora Marín-de; Pogoutse, Oxana; Strobel, Alexandra; Schwehn, Patrick; Li, Roujia; Rothballer, Simin T; Altmann, Melina; Cassonnet, Patricia; Coté, Atina G; Vergara, Lena Elorduy; Hazelwood, Isaiah; Liu, Betty B; Nguyen, Maria; Pandiarajan, Ramakrishnan; Dohai, Bushra; Coloma, Patricia A Rodriguez; Poirson, Juline; Giuliana, Paolo; Willems, Luc; Taipale, Mikko; Jacob, Yves; Hao, Tong; Hill, David E; Brun, Christine; Twizere, Jean-Claude; Krappmann, Daniel; Heinig, Matthias; Falter, Claudia; Aloy, Patrick; Demeret, Caroline; Vidal, Marc; Calderwood, Michael A.
Afiliação
  • Kim DK; Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada.
  • Weller B; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Lin CW; Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System, Toronto, Ontario, Canada.
  • Sheykhkarimli D; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Knapp JJ; Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Dugied G; Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
  • Zanzoni A; Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
  • Pons C; Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada.
  • Tofaute MJ; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Maseko SB; Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System, Toronto, Ontario, Canada.
  • Spirohn K; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Laval F; Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada.
  • Lambourne L; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Kishore N; Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System, Toronto, Ontario, Canada.
  • Rayhan A; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sauer M; Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, Institut Pasteur, Paris, France.
  • Young V; UMR3569, Centre National de la Recherche Scientifique, Paris, France.
  • Halder H; Université de Paris, Paris, France.
  • la Rosa NM; Aix-Marseille Université, Inserm, TAGC, Marseille, France.
  • Pogoutse O; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute for Science and Technology, Barcelona, Spain.
  • Strobel A; Research Unit Cellular Signal Integration, Institute of Molecular Toxicology and Pharmacology, Molecular Targets and Therapeutics Center (MTTC), Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
  • Schwehn P; Laboratory of Viral Interactomes, GIGA Institute, University of Liège, Liège, Belgium.
  • Li R; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Rothballer ST; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Altmann M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cassonnet P; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Coté AG; Laboratory of Viral Interactomes, GIGA Institute, University of Liège, Liège, Belgium.
  • Vergara LE; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Hazelwood I; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Liu BB; TERRA Teaching and Research Centre, University of Liège, Gembloux, Belgium.
  • Nguyen M; Laboratory of Molecular and Cellular Epigenetics, GIGA Institute, University of Liège, Liège, Belgium.
  • Pandiarajan R; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dohai B; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Coloma PAR; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Poirson J; Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada.
  • Giuliana P; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Willems L; Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System, Toronto, Ontario, Canada.
  • Taipale M; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jacob Y; Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada.
  • Hao T; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Hill DE; Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System, Toronto, Ontario, Canada.
  • Brun C; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
  • Twizere JC; Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
  • Krappmann D; Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
  • Heinig M; Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
  • Falter C; Institute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
  • Aloy P; Donnelly Centre for Cellular and Biomolecular Research (CCBR), University of Toronto, Toronto, Ontario, Canada.
  • Demeret C; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Vidal M; Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System, Toronto, Ontario, Canada.
  • Calderwood MA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.
Nat Biotechnol ; 41(1): 140-149, 2023 01.
Article em En | MEDLINE | ID: mdl-36217029
Understanding the mechanisms of coronavirus disease 2019 (COVID-19) disease severity to efficiently design therapies for emerging virus variants remains an urgent challenge of the ongoing pandemic. Infection and immune reactions are mediated by direct contacts between viral molecules and the host proteome, and the vast majority of these virus-host contacts (the 'contactome') have not been identified. Here, we present a systematic contactome map of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the human host encompassing more than 200 binary virus-host and intraviral protein-protein interactions. We find that host proteins genetically associated with comorbidities of severe illness and long COVID are enriched in SARS-CoV-2 targeted network communities. Evaluating contactome-derived hypotheses, we demonstrate that viral NSP14 activates nuclear factor κB (NF-κB)-dependent transcription, even in the presence of cytokine signaling. Moreover, for several tested host proteins, genetic knock-down substantially reduces viral replication. Additionally, we show for USP25 that this effect is phenocopied by the small-molecule inhibitor AZ1. Our results connect viral proteins to human genetic architecture for COVID-19 severity and offer potential therapeutic targets.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá